Simple blood test for early diagnosis of Alzheimer’s disease

Technology Development

Business Development



Visit Website
Contact Us
Follow Us


NeuroQuest has discovered blood-based immune biomarkers in Alzheimer’s patients that measure unique aspects of the immune system that reflect the disease pathology and can be used for diagnosis, prognosis, and monitoring of disease progression. These patented biomarkers may provide a better understanding of the mechanism of neurodegenerative disease, leading to improved therapeutics.

NeuroQuest’s simple blood screening test for populations aged 60 and older is based on the peripheral immune system to address the urgent need for an accurate diagnostic test to enable early treatment. The test will serve as an affordable, accurate, accessible surrogate to PET scans, indicating formation of brain amyloid plaques in the preclinical stage of Alzheimer’s.

Biomarker tests will be essential to identify which individuals are in the early stages of Alzheimer’s and should receive disease-modifying treatment.

Market Need

Worldwide, approximately 50 million people have Alzheimer’s disease or a related form of dementia. Despite intense efforts by the medical community, current tests used to diagnose Alzheimer’s in its early stages — when intervention offers the most hope — have limited use due to their costs and reliability.

According to Alzheimer’s Disease International, the global cost of Alzheimer’s and dementia is estimated to be at almost 1% of the world’s GDP. An accurate, affordable blood test will ease the burden of late-stage diagnosis on families and the health care system and facilitate the development of vaccines and targeted therapeutics.

Skip to content